<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02686983</url>
  </required_header>
  <id_info>
    <org_study_id>DHC-GON-1</org_study_id>
    <nct_id>NCT02686983</nct_id>
  </id_info>
  <brief_title>GON-block in Chronic Migraine: a Randomized, Double- Blind, Placebo-controlled Study</brief_title>
  <acronym>DHC-GON-1</acronym>
  <official_title>Greater Occipital Nerve Blockade for the Treatment of Chronic Migraine: a Randomized, Double- Blind, Placebo-controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jakob Møller Hansen, MD.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Danish Headache Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Infiltration of the greater occipital nerve (GON) with local anaesthetics and corticosteroids
      is a treatment option for cluster headache. Corticosteroids may be helpful in reducing the
      pain intensity and frequency in chronic migrtaine. This RCT is set up to assess efficacy and
      safety of sub-occipital steroid injections with local anesthetic in patients with chronic
      migraine.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Infiltration of the greater occipital nerve (GON) with local anaesthetics and corticosteroids
      is a treatment option for cluster headache. In general, there is a marked paucity of evidence
      concerning GON blocks in migraine. Corticosteroids may be helpful in reducing the pain
      intensity and frequency in these patients. This is an RCT to assess efficacy and safety of
      sub-occipital steroid injections with local anesthetic in patients with chronic migraine.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>March 2016</start_date>
  <completion_date type="Anticipated">July 2018</completion_date>
  <primary_completion_date type="Anticipated">March 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of migraine days</measure>
    <time_frame>8 weeks</time_frame>
    <description>Number of days fulfilling the ICHD criteria for migraine</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of days with severe headache days</measure>
    <time_frame>8 weeks</time_frame>
    <description>Number of days with severe headache days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Medication use</measure>
    <time_frame>8 weeks</time_frame>
    <description>use of medication recorded during the 8 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Responder rate</measure>
    <time_frame>8 weeks</time_frame>
    <description>number of patients with more than 50% reduction in migraine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of migraine attacks</measure>
    <time_frame>8 weeks</time_frame>
    <description>Number of attacks fulfilling the ICHD criteria for migraine</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">34</enrollment>
  <condition>Chronic Migraine</condition>
  <arm_group>
    <arm_group_label>Active</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Betamethasone and local anesthetic.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Saline with local anesthetic.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Betamethasone and local anesthetic</intervention_name>
    <description>Infiltration of the greater occipital nerve .</description>
    <arm_group_label>Active</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>GON block</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Chronic migraine

        Exclusion Criteria:

          -  Medication overuse headache
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jakob M Hansen, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Danish Headache Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jakob Møller Hansen</last_name>
    <email>jamoha01@regionh.dk</email>
  </overall_contact>
  <location>
    <facility>
      <name>Danish Headache Center, University of Copenhagen, Faculty of Health Sciences, Department of Neurology, Glostrup Hospital</name>
      <address>
        <city>Glostrup, Copenhagen</city>
        <zip>2600</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>February 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 12, 2016</study_first_submitted>
  <study_first_submitted_qc>February 19, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 22, 2016</study_first_posted>
  <last_update_submitted>February 22, 2016</last_update_submitted>
  <last_update_submitted_qc>February 22, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 23, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Danish Headache Center</investigator_affiliation>
    <investigator_full_name>Jakob Møller Hansen, MD.</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Migraine Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anesthetics</mesh_term>
    <mesh_term>Anesthetics, Local</mesh_term>
    <mesh_term>Betamethasone benzoate</mesh_term>
    <mesh_term>Betamethasone-17,21-dipropionate</mesh_term>
    <mesh_term>Betamethasone</mesh_term>
    <mesh_term>Betamethasone Valerate</mesh_term>
    <mesh_term>Betamethasone sodium phosphate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

